The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis
- 1 January 2020
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 19 (1), 102421
- https://doi.org/10.1016/j.autrev.2019.102421
Abstract
No abstract availableKeywords
This publication has 125 references indexed in Scilit:
- Janus kinase inhibitors in autoimmune diseasesAnnals Of The Rheumatic Diseases, 2013
- Back to the future: oral targeted therapy for RA and other autoimmune diseasesNature Reviews Rheumatology, 2013
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)The Journal of Immunology, 2011
- Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular diseaseAnnals Of The Rheumatic Diseases, 2011
- Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007Arthritis & Rheumatism, 2010
- Synovial fibroblasts spread rheumatoid arthritis to unaffected jointsNature Medicine, 2009
- What effects might anti-TNF treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF in cardiovascular pathophysiologyAnnals Of The Rheumatic Diseases, 2007